![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
Details:
Actonel (risedronate sodium hydrate) tablet act as inhibits osteoclasts, which is indicated for the treatment of Paget’s disease and treatment and prevention of postmenopausal osteoporosis.
Lead Product(s): Risedronate Sodium
Therapeutic Area: Rare Diseases and Disorders Product Name: Actonel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2020